18 October 2017 - Melbourne, Australia. Sienna Cancer Diagnostics Ltd (“Sienna” or “the Company”), (ASX:SDX), a commercial stage medical technology company focused on the development and commercialisation of innovative cancer-related tests for the diagnostic pathology market, has today released its Appendix 4C Quarterly Cash Flow report for the quarter ending 30 September 2017.
The cash balance at 30 September was $4.1 million, with net cash inflow for the quarter totalling $3.4 million. New capital issued through the Company’s IPO contributed $4.4 million during the quarter and receipts from product sales were $243,000.
For further information please download PDF attached:
Download this document
